Major categories of antithrombotic therapy include agents that target any one of three main components of the thrombotic process: thrombin, platelets, or fibrin.
- IIb/IIIa (tirofiban, eptifibatide, abciximab) inhibitors
- Antiplatelet agents
- Thrombin inhibitors
Injury to the endothelium exposes receptors that promote the adhesion of platelets at the site of injury. The platelet surface is where all the chain reactions in the coagulation cascade occur. Activated platelets express 80,000 receptor sites per platelet when trying to adhere and aggregate. During platelet activation glycoprotein 2b/3a (GP Iib/IIIa) receptors are activated allowing fibrinogen molecules and Von Willebrand factor link adjacent platelets to form an aggregate. The process of aggregation takes place within 15-20 seconds of the injury, binding the platelets together that ultimately results in the formation of a thrombus (clot).
Manufacturers / Products
- ReoPro (abciximab)
- Integrilin (eptifibatide)